GIGABYTE
21.5.2024 03:01:30 CEST | Business Wire | Press release
GIGABYTE Technology, a leading IT innovator, is at the forefront of advancing global industries through cloud and AI computing systems, enhancing user experiences through hardware innovation. At COMPUTEX 2024, GIGABYTE unveils groundbreaking products poised to define the AI era.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240517872510/en/
GIGABYTE Showcases a Whole Lot of Computing Power at COMPUTEX, Taking the AI-driven New Evolution Head-On (Graphic: Business Wire)
Building on last year’s success, GIGABYTE looks to solidify its AI leadership with the theme “ACCEVOLUTION,” reflecting the increasing demand for computing and GIGABYTE’s ability to “accelerate the next evolution.” With its largest-ever presence at COMPUTEX, GIGABYTE’s booth stands as the largest single-brand exhibit. Showcasing a wide range of products, solutions, and applications aligned with the AI trend, GIGABYTE covers key tech trends including AI computing, advanced connectivity, future mobility, immersive reality, sustainability, and innovation.
GIGABYTE’s remarkable advancements in AI server development in recent years have garnered widespread attention, as GIGABYTE introduced the G593-SD0, the world’s first and only NVIDIA-certified 5U AI server to efficiently support the HGX™ H100 8 x SXM5. GIGABYTE further expands its super AI server lineup with ARM-based AI servers featuring the next-generation Grace Hopper™ superchip, and AI servers supporting AMD’s next-gen superchips MI300X GPU and MI300A APU. This year, on top of the upgraded H200 GPU, with NVIDIA unveiling the Blackwell architecture, GIGABYTE will showcase ahead of schedule at its booth the latest high-density servers compatible with GPUs such as B100 and B200. The highly-anticipated GB200 will also be demonstrated in a liquid-cooled cabinet as GB200 NVL72, acting as one massive GPU that can achieve 30 times the inference performance of the same amount of H100 GPUs. This allows visitors not only to witness these innovations firsthand but also to engage in discussions with professionals about the future of AI development and computing deployment.
As AI becomes ubiquitous, computing demand rises sharply in large data centers and AI startups. At this year’s COMPUTEX, GIGABYTE presents GIGA POD, a scalable rack integration solution, designed to meet data center-level deployments. Beyond showing GIGA POD’s comprehensive hardware and software integration and AI training optimization environments, on-site demonstrations will highlight its performance leadership and deployment flexibility.
GIGABYTE’s AI development encompasses GPU parallel computing, data storage, and network transmission in data centers. GIGABYTE’s R&D prowess is evident in industry-leading thermal and mechanical design, while modular design enables product diversity, speeding up time-to-market. At the booth, find servers for cloud to edge computing, high-performance to high-density storage, and computing options for SMBs and micro-enterprises, including DIY server motherboards tailored to AI development at various scales.
GIGABYTE’s green computing complements AI advancements perfectly. Innovations like Direct Liquid Cooling and Immersion Cooling redefine performance and efficiency, offering comprehensive setups for servers and cabinets. This enables servers with the latest chips from AMD, Intel, and NVIDIA to surpass traditional cooling limits, enhancing heat dissipation and computational density while ensuring stability. GIGABYTE’s sustainability commitment is evident in immersion cooling solutions, supporting technological advancements with optimal power usage.
GIGABYTE presents both robust AI model training capabilities and practical AI applications through industrial-grade embedded computers. Demonstrations span smart factories with AI-enabled machine vision and high-stability embedded computers for remote control, as well as retail bars utilizing panel PCs combined with AI recognition and big data analysis. Advancements in AI and next-generation CPU/GPU also bolster smart automotive applications, enhancing ADAS and in-vehicle Telematics devices.
In the consumer PC market, GIGABYTE leads with AI-enhanced products like motherboards, graphics cards, and AI gaming laptops. These feature stable AI computing power and innovative capabilities such as the AI Nexus in the AORUS 16X gaming laptop, offering applications like AI Power Gear and AI Boost. At our booth’s AI experience area, visitors can explore the latest AI applications and real-time interactions, including NVIDIA ACE and ChatRTX, delving immersively into cutting-edge AI technologies.
GIGABYTE is bringing an impressive products portfolio to COMPUTEX, demonstrating its capacity to accelerate the next evolution of technology in this changing AI landscape, and its abundance of computing solutions driven by the connectivity and velocity of data and AI can elevate businesses and empower individuals to thrive in the extra-fast growing and development time.
Visit GIGABYTE’s COMPUTEX event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240517872510/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom